Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517414 | 1.00 | CASP3 (0.49) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL24414058 | 1.00 | CASP3 (0.49) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL31045483 | 0.88 | CASP3 (0.45) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL30517410 | 0.87 | CASP3 (0.45) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29564442 | 0.85 | CASP3 (0.57) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL119043 | 0.85 | CASP3 (0.57) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29349978 | 0.85 | CASP3 (0.57) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL178736 | 0.85 | CASP3 (0.57) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29508222 | 0.85 | CASP3 (0.57) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29446045 | 0.85 | CASP3 (0.57) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182569-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |